戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 B, and IIA) and advanced stage (IIB-IV) with bulky disease.
2 002) for OS for patients not receiving RT to bulky disease.
3 tment, including nine objective responses in bulky disease.
4 and the presence or absence of B symptoms or bulky disease.
5  did not produce remissions in patients with bulky disease.
6 ged survival of tumor-bearing mice even with bulky disease.
7 nsitivity and for the presence or absence of bulky disease.
8 lidative RT, even in patients with initially bulky disease.
9 unfavorable-risk Hodgkin lymphoma, including bulky disease.
10 th newly diagnosed cHL, including those with bulky disease.
11 olidation radiotherapy, including those with bulky disease.
12  number of previous anticancer regimens, and bulky disease.
13 or patients entering clinical trials without bulky disease.
14 age I or II disease at diagnosis, and 13 had bulky disease.
15                     PET-NEG patients who had bulky disease ( 10 cm) at diagnosis had outcomes indisti
16 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanf
17 nosis (including the presence of B symptoms, bulky disease, advanced stage, or extranodal disease), r
18                                Patients with bulky disease and high-risk genetic features have achiev
19 ion-free survival even after controlling for bulky disease and International Prognostic Score more th
20 nted, includes irradiation of symptomatic or bulky disease and intracerebrospinal fluid chemotherapy
21                        There was no limit on bulky disease, and 59% had at least one mass > or = 5 cm
22                       SUVmax >/=10, PS >/=2, bulky disease, and age >/=65 were independently associat
23 ree and treatment-free interval, presence of bulky disease, and previous treatment with PI3K inhibito
24 c covariates included histology, presence of bulky disease, and prior treatment history.
25 on (cT3-4 5 cm from anal verge, any N), with bulky disease (any cT4 or tumor within 3 mm of mesorecta
26         Additive RT to bulky sites abrogates bulky disease as a risk factor and improves outcome of e
27 ced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease
28 CR rate to hu14.8-IL2, whereas patients with bulky disease did not respond.
29 cs, including bone marrow involvement (41%), bulky disease > or = 5 cm (49%), and transformed histolo
30                 Fourteen of 15 patients with bulky disease (> or = 5 cm) had a CR after treatment com
31 ad at least four prior regimens) and 49% had bulky disease (> or = 5 cm).
32          Responses occurred in patients with bulky disease (> or = 7 cm; 41%) and splenomegaly (50%).
33 ly, when controlling for the IPI, identified bulky disease (&gt;/= 10 cm), thrombocytopenia (< 150 x 10(
34 range) age of 64 (32-91) years, 34 (53%) had bulky disease (&gt;/=1 lymph nodes >/=5 cm), and 37 (58%) h
35                      On univariate analysis, bulky disease (&gt;10 cm), extranodal nonbone marrow involv
36 welve had either large mediastinal masses or bulky disease (&gt;10 cm).
37                             Four of six with bulky disease had a PR.
38                              The presence of bulky disease in Hodgkin lymphoma (HL), traditionally de
39 e (P = .025) of high Ki67, high PET SUV, and bulky disease influenced overall survival (OS) and progr
40 emotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin
41 elated with younger age, higher frequency of bulky disease, lower hemoglobin levels, higher leukocyte
42                       Eligible patients with bulky disease (mass > 10 cm or 1/3 the maximum intrathor
43 This observation suggests that patients with bulky disease may require more aggressive management.
44 ment of patients with refractory or relapsed bulky disease measuring >10 cm, and retreatment of patie
45 ents required radiation (due to unresponsive bulky disease or CNS involvement).
46 nuing to include RT in patients with initial bulky disease or residual masses.
47 a who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Coo
48 endamustine-rituximab as primary therapy for bulky disease, profound hematologic compromise, or const
49            Patients with platinum-resistant, bulky disease should not be transplanted.
50 port that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally exten
51 including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs)
52  better therapeutic results in patients with bulky disease, the application of higher, potentially my
53 , event-free survival (EFS) of patients with bulky disease was inferior without additive RT (hazard r
54 re, international prognostic score >/= 4 and bulky disease were no longer prognostic in patients who
55 , or earlier stage with systemic symptoms or bulky disease) were randomly assigned between ABVD and M